Hanon Therapeutics

Hanon Therapeutics is a biotechnology company dedicated to developing precision medicines for neurodegenerative diseases, with a primary focus on TDP-43 proteinopathies. The company's platform targets the underlying pathology of conditions such as Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD) by modulating TDP-43 function and aggregation. By leveraging deep expertise in RNA-binding proteins and proteostasis, Hanon aims to create disease-modifying therapies that address the root causes of neurodegeneration. Their lead programs are currently in the pre-clinical stage, focusing on restoring healthy protein dynamics in the central nervous system. The company was founded by world-renowned experts in TDP-43 biology and is backed by leading venture capital firms in the life sciences sector. Hanon's approach specifically addresses the loss of essential proteins like stathmin-2 that occurs when TDP-43 is dysfunctional.